Colon Targeted Drug Delivery System Dissertation Abstract

1. Das S, Deshmukh R, Jha A. Role of natural polymers in the development of multiparticulate systems for colon drug targeting. Syst Rev Pharmacy. 2010;1(1):79–85. doi: 10.4103/0975-8453.59516.[Cross Ref]

2. Leuva VR, Patel BG, Chaudhary DJ, Patel JN, Modasiya MMK. Oral colon-specific drug delivery system. J Pharm Res. 2012;5(4):2293–7.

3. Kumar M, Ali A, Kaldhone P, Shirode A, Kadam VJ. Report on pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Res. 2010;3(3).

4. Philip AK, Philip B. Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Med J. 2010;25(2):79–87. doi: 10.5001/omj.2010.24.[PMC free article][PubMed][Cross Ref]

5. Kumar P, Mishra B. Colon targeted drug delivery systems—an overview. Curr Drug Deliv. 2008;5(3):186–98. doi: 10.2174/156720108784911712.[PubMed][Cross Ref]

6. Malayandi R, Kondamudi P, Ruby PK, Aggarwal D. Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease. Drug Deliv Transl Res. 2014;4(2):187–202. doi: 10.1007/s13346-013-0185-4.[PubMed][Cross Ref]

7. Coupe AJ, Davis SS, Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res. 1991;8(3):360–4. doi: 10.1023/A:1015849700421.[PubMed][Cross Ref]

8. Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Barnett JL, et al. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res. 1990;7(7):756–61. doi: 10.1023/A:1015827908309.[PubMed][Cross Ref]

9. Ibekwe VC, Fadda HM, McConnell EL, Khela MK, Evans DF, Basit AW. Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm Res. 2008;25(8):1828–35. doi: 10.1007/s11095-008-9580-9.[PubMed][Cross Ref]

10. Rubinstein A. Microbially controlled drug delivery to the colon. Biopharm Drug Dispos. 1990;11(6):465–75. doi: 10.1002/bdd.2510110602.[PubMed][Cross Ref]

11. Hebden JM, Blackshaw PE, Perkins AC, Wilson CG, Spiller RC. Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther. 2000;14(2):155–61. doi: 10.1046/j.1365-2036.2000.00697.x.[PubMed][Cross Ref]

12. Rana SV, Sharma S, Malik A, Kaur J, Prasad KK, Sinha SK, et al. Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease. Dig Dis Sci. 2013;58(9):2594–8. doi: 10.1007/s10620-013-2694-x.[PubMed][Cross Ref]

13. Stubbs JB, Valenzuela GA, Stubbs CC, Croft BY, Teates CD, Plankey MW, et al. A noninvasive scintigraphic assessment of the colonic transit of nondigestible solids in man. J Nucl Med. 1991;32(7):1375–81.[PubMed]

14. Christl SU, Scheppach W. Metabolic consequences of total colectomy. Scand J Gastroenterol Suppl. 1997;222:20–4.[PubMed]

15. Sandle GI. Salt and water absorption in the human colon: a modern appraisal. Gut. 1998;43(2):294–9. doi: 10.1136/gut.43.2.294.[PMC free article][PubMed][Cross Ref]

16. Schiller C, Frohlich CP, Giessmann T, Siegmund W, Monnikes H, Hosten N, et al. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2005;22(10):971–9. doi: 10.1111/j.1365-2036.2005.02683.x.[PubMed][Cross Ref]

17. Shameem M, Katori N, Aoyagi N, Kojima S. Oral solid controlled release dosage forms: role of GI-mechanical destructive forces and colonic release in drug absorption under fasted and fed conditions in humans. Pharm Res. 1995;12(7):1049–54. doi: 10.1023/A:1016270701021.[PubMed][Cross Ref]

18. Pijper A, Discombe G. Shape and motility of bacteria. J Pathol Bacteriol. 1946;58(3):325–42. doi: 10.1002/path.1700580302.[PubMed][Cross Ref]

19. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut. 1988;29(8):1035–41. doi: 10.1136/gut.29.8.1035.[PMC free article][PubMed][Cross Ref]

20. Fallingborg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, Rasmussen HH. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther. 1989;3(6):605–13. doi: 10.1111/j.1365-2036.1989.tb00254.x.[PubMed][Cross Ref]

21. Macfarlane GT, Gibson GR, Cummings JH. Comparison of fermentation reactions in different regions of the human colon. J Appl Bacteriol. 1992;72(1):57–64.[PubMed]

22. Bown RL, Gibson JA, Sladen GE, Hicks B, Dawson AM. Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device. Gut. 1974;15(12):999–1004. doi: 10.1136/gut.15.12.999.[PMC free article][PubMed][Cross Ref]

23. Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001;48(4):571–7. doi: 10.1136/gut.48.4.571.[PMC free article][PubMed][Cross Ref]

24. Gibson SA, McFarlan C, Hay S, MacFarlane GT. Significance of microflora in proteolysis in the colon. Appl Environ Microbiol. 1989;55(3):679–83.[PMC free article][PubMed]

25. Rowland IR. Factors affecting metabolic activity of the intestinal microflora. Drug Metab Rev. 1988;19(3–4):243–61. doi: 10.3109/03602538808994135.[PubMed][Cross Ref]

26. Chung KT, Fulk GE, Egan M. Reduction of azo dyes by intestinal anaerobes. Appl Environ Microbiol. 1978;35(3):558–62.[PMC free article][PubMed]

27. Hejazi R, Amiji M. Chitosan-based gastrointestinal delivery systems. J Control Release. 2003;89(2):151–65. doi: 10.1016/S0168-3659(03)00126-3.[PubMed][Cross Ref]

28. Ratner BD, Gladhill KW, Horbett TA. Analysis of in vitro enzymatic and oxidative degradation of polyurethanes. J Biomed Mater Res. 1988;22(6):509–27. doi: 10.1002/jbm.820220607.[PubMed][Cross Ref]

29. Sinha VR, Kumria R. Polysaccharides in colon-specific drug delivery. Int J Pharm. 2001;224(1–2):19–38. doi: 10.1016/S0378-5173(01)00720-7.[PubMed][Cross Ref]

30. Kang M, Khanal T, Kim H, Lee D, Yeo H, Lee Y, et al. Role of metabolism by human intestinal microflora in geniposide-induced toxicity in HepG2 cells. Arch Pharm Res. 2012;35(4):733–8. doi: 10.1007/s12272-012-0418-y.[PubMed][Cross Ref]

31. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol. 1984;7(1):35–49. doi: 10.1097/00002826-198403000-00002.[PubMed][Cross Ref]

32. Azadkhan AK, Truelove SC, Aronson JK. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol. 1982;13(4):523–8.[PMC free article][PubMed]

33. Hamedani R, Feldman RD, Feagan BG. Drug development in inflammatory bowel disease: budesonide-a model of targeted therapy. Aliment Pharmacol Ther. 1997;3:98–107.[PubMed]

34. French DL, Mauger JW. Evaluation of the physicochemical properties and dissolution characteristics of mesalamine: relevance to controlled intestinal drug delivery. Pharm Res. 1993;10(9):1285–90. doi: 10.1023/A:1018909527659.[PubMed]

Administering drugs orally is by far the most widely used route of administration that will help eliminate the pain caused by injection, psychological barriers associated with multiple daily injections and possible infection from injection sites. However, it is important for oral drug administration to overcome several different obstacles during the delivery through the gastrointestinal tract. The barriers can be morphological barriers and physiological factors such as a wide range of pH and enzymatic activities. The lower water content and fluid mobility of the colon, which leads to longer retention times and also lower proteolytic activity of colon compared to other areas of the gastrointestinal tract, make the colon an ideal site for both systemic and local delivery of drugs. Therefore aggressive research efforts have recently focused on development of new strategies for delivering drugs to the colon. As a drug delivery systems, hydrogels have received increasing attention due to their outstanding merits. Among the various hydrogels, including natural, synthetic and natural/synthetic hybrid hydrogels, chitosan has attracted significant attention in a broad range of pharmaceutical and biomedical applications. Chitosan is a hydrophilic polyelectrolyte heteropolysaccharide composed of randomly (1→4)-linked 2- acetamido-2-deoxy-β-D-glucopyranose and 2-amino-2-deoxy-β-D-glucopyranose linked by (1→4)-β-glycosidic bonds. Unlike most known bioadhesive polymers, chitosan displays unique pharmaceutical and biomedical applications due to the large number of hydroxy and amino groups on the backbone of chitosan. These functional groups can be readily modified. This study was commenced with the aim of engineering a carrier with high enough physicochemical stability to reach the colon and to be able to protect a drug from various obstacles throughout the gastrointestinal tract. In this study, a new generation of chitosan derivatives was developed. Furthermore, their viability was investigated for potential applications as drug carriers to the colon. Chitosan based films with improved physical properties from introducing a cyclic imide moiety into the chitosan matrices was developed and characterised. Mechanical, thermal and chemical analyses of these films show that the heterocyclic imide linkage imparts excellent thermal, mechanical and chemical stability to the chitosan film. Additionally, spray dried chitosan microspheres with improved mechanical stability were examined for the controlled drug release of bovine serum albumin as a model protein drug. Additionally, a novel generation of amphoteric crosslinked chitosan derivatives was designed to be pH sensitive and bacterially degradable. Tabletted carriers were designed to protect the drug from the harsh acidic environment of the stomach and the rigorous enzymic activity of the small intestine and deliver the drug to the colon. Tabletted formulation forms of these novel amphoteric derivatives of chitosan showed the excellent potential formulations as colon specific drug delivery vehicles.


The Author

Massey University

The following journal articles have been removed due to copyright restrictions: Kavianinia, I.; Plieger, P. G.; Kandile, N. G.; Harding, D. R., Fixed-bed column studies on a modified chitosan hydrogel for detoxification of aqueous solutions from copper (II). Carbohydrate Polymers. 2012, 90 (2), 875–886; Kavianinia, I.; Plieger, P. G.; Kandile, N. G.; Harding, D. R., New hydrogels based on symmetrical aromatic anhydrides: Synthesis, characterization and metal ion adsorption evaluation, Carbohydrate Polymers. 2012, 87 (1), 881–893; Kavianinia, I.; Plieger, P. G.; Kandile, N. G.; Harding, D. R., In Vitro Evaluation of Spray-Dried Chitosan Microspheres Crosslinked with Pyromellitic Dianhydride for Oral Colon-Specific Delivery of Protein Drugs. Article first published online: 13 Feb 2013.


Show full item record

Categories: 1

0 Replies to “Colon Targeted Drug Delivery System Dissertation Abstract”

Leave a comment

L'indirizzo email non verrà pubblicato. I campi obbligatori sono contrassegnati *